ABBOTT LABORATORIES — Director's Dealing 2020

Feb 25, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2020-02-21

Reporting Person: WHITE MILES D (Director, Chairman and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-21	Common shares without par value	A	68399	—	Acquired	3228870	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-21	Option (right to buy)	$87.72	A	416956	Acquired	2030-02-20	Common shares (416956)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	34561	Indirect

Footnotes

F1: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

F2: Balance in the Abbott Laboratories Stock Retirement Trust as of February 21, 2020.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 138,985 on February 21, 2021, 138,985 on February 21, 2022, and 138,986 on February 21, 2023.